Abstract
Background: A new method to measure the cholinergic status with quantitative electroencephalography (qEEG) to distinguish healthy from early dementia patients and identify responders of Acetylcholinesterase inhibitor treatment. The objective is to evaluate cognition via Mini Mental Score Examination (MMSE) at baseline and follow-up examination after approximately 2 years for patients with suspected dementia and comparison with the predictive baseline values for (qEEG) and Cerebro-spinal fluid (Csf) biomarkers. If qEEG predicts the cognitive decline best, a noninvasive and inexpensive method is offering the possibility to start Acetylcholinesterase inhibitor treatment early in the dementia disease course. Methods: The average power of four qEEG epochs with eyes closed (E.Cl.) and open eyes (E.O.), and the ratio of E.O. / E.Cl. (Vigilance-index), and average peak frequency of E.Cl. epochs, calculated. The Csf parameters; total-Tau, phospho-Tau, and Amyloid β-42 analyzed. The correlation between the number of pathological MMSE-scores and pathological values of baseline biomarkers evaluated. Results: The Spearman rank correlation between MMSE revealed no linear relation for the examined biomarkers. When comparison of pathological values for MMSE at follow up after approximately 2 years the sensitivity to identify from the baseline values for qEEG and Csf biomarkers, found Vigilanceindex to have the highest sensitivity (1.0) then total-Tau (0.5) and the rest parameters lower, lowest for the combination of Csf parameters (0,09) to predict cognitive decline. The specificity for the baseline Vigilance-index was (0.87) and for total-Tau (0.39) and lower for the other parameters at the follow-up examination. Conclusion: Vigilance-index best reflects the cognitive decline after two years in early dementia disease, by measuring cholinergic deficit, compared to Csf biomarkers to measure total-Tau, phospho-Tau, and Amyloid β-42.
Highlights
The introduction of Acetylcholinesterase inhibitors (AChEI) as a symptomatic treatment of Alzheimer’s disease (AD) has made patients seek medical advice at an earlier stage of the disease. This circumstance has highlighted the importance of diagnostic markers for early dementia, that indicates progressive dementia, such as for Alzheimers (AD), and Lewy body dementia (LBD)
There is no clinical method to determine which of the patients with mild cognitive impairment (MCI) that will progress to AD and LBD dementia, or have a benign form of MCI without progression
Essential to underline is that the statistical analysis of sensitivity, specificity, positive predictive value, and negative predictive values are not for identifying a diagnose but for mini-mental score examination (MMSE) scores, pathological or non-pathological values related to the examined variables
Summary
The introduction of Acetylcholinesterase inhibitors (AChEI) as a symptomatic treatment of Alzheimer’s disease (AD) has made patients seek medical advice at an earlier stage of the disease This circumstance has highlighted the importance of diagnostic markers for early dementia, that indicates progressive dementia, such as for Alzheimers (AD), and Lewy body dementia (LBD). The Vigilance-index reflects the cholinergic status and could be shown to be affected by Acetylcholinesterase inhibitor medication in a positive direction, hindering further decrease in primary degenerative dementia, which known to decrease in Alzheimers dementia [1523] This circumstance could potentially lead to earlier identification of those patients developing AD and LBD as well as the initiation of Acetylcholinesterase inhibitor treatment earlier in the course of the disease than previous EEG methods [5,24,25,26,27,28,29,30]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
